EWTX Q1 2023 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$23M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$27M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$346M

Total Liabilities

$18M

Stockholders' Equity

$329M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$15M	-73.4%
Net Income	-$23M	-$15M	-55.8%